FDA Approves Cabozantinib for Hepatocellular Carcinoma
Approval is based on results from the CELESTIAL trial
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Approval is based on results from the CELESTIAL trial
FDA Approves Longer-acting Calaspargase Pegol-mknl for ALL
EndoPredict, Oncotype DX Breast Recurrence Score and Prosigna are recommended, while MammaPrint and IHC4+C are not
CD123-directed cytotoxin is indicated in adults and in paediatric patients
A series of articles published in the Nature Medicine highlight new technologies that are transforming medicine and healthcare
Approval is based on results from the KEYNOTE-017 study
Patients should be selected for therapy based on an FDA-approved companion diagnostic
Herzuma is indicated for the treatment of HER2-overexpressing breast cancer
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.